Stay alert to the latest and greatest on stem cells. Enjoy this week’s “3 Bullet Thursday,” a weekly post that we do to update you on interesting and important events within the world of stem cells.
(1) The world’s first clinical trial to inject stem cells into the womb was announced. The trial, starting in January 2016, will be headed by Sweden’s Karolinska Institute and the UK’s Great Ormond Street Hospital. It will seek to address osteogenesis imperfecta, or “brittle bone disease,” by using injected stem cells to correct errors within the fetal DNA.
(2) A research team in Australia succeeded at creating the first kidney organoids and the beginnings of an intestine. This accomplishment represents a step forward toward the creation of clinically useful organs for transplantation. This is an area of regenerative medicine where “science fiction” is moving toward “science fact.”
(3) Cynata Therapeutics continues to reveal more about their technology for economical, consistent, and robust production of mesenchymal stem cells (MSC), positioning it as one of the first companies that could make stem cell-based therapeutics a practical reality. Commercial-scale manufacture of stem cells is arguably the single largest hurdle in bringing stem cell therapies to market, making this company my weekly pick as a stem cell company “to watch.”
BONUS: I spent this past week in Boston, MA, for the ultimate biobanking event of 2015, the “Biorepositories and Sample Management Summit.” I met brilliant thought leaders in biobanking, and importantly, have summarized all of the most critical market trends for you here in my summary of Day 1 and Day 2.
Want to get this fun weekly update? Join below and we’ll keep you in the loop, starting next week!